In a pilot study with a small number of patients with and without T2DM, 72 h of intravenous GLP-1 infusion to patients with ACS undergoing percutaneous revascularization improved left ventricular ejection fraction (LVEF) and regional wall motility [147]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.